Overview

A Prospective, Open-label, Single-arm Phase II Clinical Study of Fruquintinib Combined With S-1 for the Treatment of Metastatic Colorectal Cancer.

Status:
NOT_YET_RECRUITING

Trial end date:
2027-02-01

Target enrollment:

Participant gender:

Summary

Exploring the efficacy and safety of fruquintinib combined with S-1 for second-line and beyond treatment in patients with advanced colorectal cancer.

Phase:

PHASE2

Details

Lead Sponsor:

Fujian Cancer Hospital